- Home
- BRT vs LCTX Comparison
BRT vs LCTX Comparison
Compare BRT & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | LCTX |
|---|---|---|
| Founded | 1972 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.0M | 251.4M |
| IPO Year | 1994 | 1996 |
Fundamental Metrics
Financial Performance| Metric | BRT | LCTX |
|---|---|---|
| Price | $13.36 | $0.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $18.00 | $5.50 |
| AVG Volume (30 Days) | 57.2K | ★ 1.5M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $97,028,000.00 | $14,556,000.00 |
| Revenue This Year | $1.10 | $4.38 |
| Revenue Next Year | $7.98 | $10.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.46 | ★ 53.24 |
| 52 Week Low | $13.13 | $0.88 |
| 52 Week High | $15.63 | $2.09 |
Technical Indicators
Market Signals| Indicator | BRT | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 45.62 |
| Support Level | $13.18 | $0.88 |
| Resistance Level | $14.87 | $1.18 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 45.90 | 39.70 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.